When lower cancer drug

Pills for those at high risk
get lukewarm reception
because of side effects

BY TARA PARKER-POPE

If someone invented a pill to cut a
cancer risk in half, would you take it?

Who wouldn’t?

Apparently the answer is millions of
women, including Cindy Birkhold of
Sarasota, Florida.

The pill is tamoxifen, and Ms. Birk-
hold, now 52, was considered an ideal
candidate for it: she tested positive for a
breast cancer gene, her mother had
ovarian cancer, and her aunt had breast
cancer. Yet rather than take tamoxifen,
she opted for surgery to remove her
breasts and ovaries.

“I even went so far as to get the pre-
scription” for tamoxifen, she said. “But
then I started reading more and decided
this isn’t the way I’m going to go. I don’t
like to take drugs.”

Such decisions have become a topic of
growing concern among doctors and re-
searchers, who are increasingly focused
on treatments to prevent cancer in high-
risk patients.

While many kinds of cancer are resis-
tant to such treatments, tamoxifen is
well documented to prevent breast can-
cer in many women who are at high risk
for it. Now another drug, raloxifene, has
been shown to have a similar effect, and
a class of drugs called aromatase inhib-
itors may also be useful. And for men,
finasteride has been shown to lower the
risk of prostate cancer.

But none of these new chemopreven-
tion drugs will do any good if patients do
not use them. University of Michigan
set out to learn why they don’t.

A woman is considered to be at high
risk for breast cancer if she is over 40
and has a mother, sister or daughter
with the disease, or has a history of
atypical cells on a breast biopsy. Tamox-
ifen lowers a woman’s risk for develop-
ing breast cancer by interfering with
the activity of estrogen in the body.

The researchers looked at 632 women
whose own mother had breast cancer,
who had a five-year risk of 1.9 percent, ac-
cording to the Gail risk score, a widely
accepted statistical model. That means
that among 1,000 similar women, 19
would be expected to develop breast
cancer over the next five years.

If those women all took tamoxifen,
however, nine of those women would
avoid breast cancer — and, as a bonus,
13 would avoid broken bones from os-
toporosis.

It is true that tamoxifen can have side
effects, some of them serious. Among
odds aren’t enough

While these risks are not to be taken lightly, neither are the risks of not using tamoxifen; its benefits for breast and bone cancer are substantial. Yet virtually every woman in the study said that she would be unlikely to take the drug. Just 6 percent said they would consider its use after talking to their doctors, and only 1 percent reported actually filling a prescription for it. Fully 90 percent cited worries about side effects.

“When the numbers were laid out for them in a way they could clearly understand, they weren’t interested in taking tamoxifen,” said Dr. Angela Fagerlin, associate professor of internal medicine at the University of Michigan and the lead author of the study, published in the journal Breast Cancer Research and Treatment. “They didn’t think the benefits of tamoxifen outweighed the risks.”

Dr. Fagerlin has also conducted a study of women and raloxifene, which has been shown to significantly reduce breast cancer risk but with fewer side effects. Although the data have not yet been published, she said the findings appeared to be similar.

Some women say that they simply do not want to take a pill every day. In fact, studies show that most people are willing to take pills if they are convinced of the benefits. Millions of women take daily birth control pills, and few people seem reluctant to take multivitamins, or aspirin to prevent heart attacks.

But in the case of anticancer drugs, a phenomenon known as “ominous bias” appears to be at work. People tend to worry more about a low risk of harm from something they do (like taking a pill or a vaccine) than about a higher risk of harm from doing nothing.

In a seminal study of vaccination trends for whooping cough in 1994, researchers from the University of Pennsylvania found that parents gave far more credence to hypothetical concerns about side effects than about the very real danger of an unvaccinated child becoming severely ill with the disease.

“I think this involves complex human psychology,” said Dr. Larry Norton, deputy physician in chief for breast cancer programs at Memorial Sloan-Kettering Cancer Center in New York. “A number of studies have shown that people are more concerned about losing something than they are about gaining something.”

Dr. Norton said that he was optimistic that new research into aromatase inhibitors, which lower the amount of estrogen in the body, would lead to new prevention options with less bothersome side effects. Meanwhile, he said, it was unlikely that large numbers of healthy women would ever be persuaded to take tamoxifen as a breast cancer prevention drug.

“It’s not a matter of being right or wrong,” he said. “The drug has been available for a long period of time, and the public is as educated as it can be, and we still haven’t seen a great use of the drug.”